Company profile
Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SPR-741 | phase1 | — | 2 | no active trials |
| TEBIPENEM PIVOXIL HYDROBROMIDE | phase1 | — | 1 | no active trials |
| Upleganan | phase1 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03792308 | phase1 | completed | 2018-12-18 | 2019-12-23 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers |
| NCT03022175 | phase1 | completed | 2016-12-01 | 2017-07-01 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers |
| NCT04238195 | phase1 | completed | 2020-01-19 | 2020-02-26 | Spero Therapeutics | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects |
| NCT06059846 | phase3 | completed | 2023-12-21 | 2025-01-27 | Spero Therapeutics | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT03796910 | phase1 | completed | 2018-12-18 | 2019-09-24 | Spero Therapeutics | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers |
FDA applications (0)
No records yet.